This study protocol was designed to systematically investigate the potential chondroprotective effects of Fructus Xanthii extract in osteoarthritis through integrated multi-omics analyses and in vivo experiments.
Research Article
* These authors contributed equally
This study protocol was designed to systematically investigate the potential chondroprotective effects of Fructus Xanthii extract in osteoarthritis through integrated multi-omics analyses and in vivo experiments.
Osteoarthritis (OA) is a progressive degenerative joint disorder for which current pharmacological and surgical interventions mainly relieve symptoms rather than reverse the underlying pathological changes, highlighting the urgent need for novel therapeutic agents. This protocol aimed to investigate the potential chondroprotective effects of Fructus Xanthii extract against OA. First, non-targeted metabolomics profiling was conducted using ultra-high-performance liquid chromatography coupled with high-resolution tandem mass spectrometry (UHPLC-HRMS/MS) to characterize the chemical constituents of the extract. An integrated strategy combining network pharmacology and transcriptomic mining was then applied to identify bioactive components and putative targets of the extract, followed by cross-analysis with OA-related dysregulated genes to obtain core target genes. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to annotate the main biological processes and signaling pathways modulated by the extract. For in vivo validation, zebrafish cartilage injury models and mouse OA models were used to evaluate the chondroprotective effects of the extract. RNA sequencing (RNA-seq) was further adopted to analyze transcriptomic alterations in chondrocytes after treatment, focusing on OA-associated pathways and gene expression profiles; enzyme-linked immunosorbent assay (ELISA) was subsequently performed to verify the expression levels of key proteins/receptors screened by RNA-seq, so as to further confirm the regulatory effects of Fructus Xanthii extract on core OA targets. This integrated multi-omics and experimental protocol provides a systematic approach to explore the potential of Fructus Xanthii extract as a promising botanical candidate for OA intervention.
Osteoarthritis (OA) is a degenerative joint disorder characterized by the progressive degradation of articular cartilage, subchondral bone sclerosis, synovial inflammation, and osteophyte formation1. According to the Global Burden of Disease (GBD) study, the prevalence of OA has steadily increased across 204 countries and territories from 1990–20202, with this trend expected to accelerate alongside global demographic ageing3. Current estimates indicate that over 250 million individuals worldwide are affected, placing significant strain on individual well-being, healthcare systems, and socioeconomic structures4. Current treatments are predominantly aimed at symptomatic relief, with non-steroidal anti-inflammatory drugs (NSAIDs) and intra-articular viscosupplementation with hyaluronic acid (HA) being the most common interventions. However, these approaches offer limited clinical benefit and are associated with considerable adverse effects5,6. This highlights the critical need for effective disease-modifying osteoarthritis drugs (DMOADs).
Traditional Chinese Medicine (TCM) has long been used in the management of OA, grounded in the concept of "bone bi," a subtype of "bi syndrome"7. In this framework, the pathogenesis of OA is attributed primarily to a deficiency in liver and kidney essence, insufficiency of qi and blood, and subsequent invasion by wind, cold, and dampness8. Accordingly, therapeutic strategies focus on dispelling wind-dampness, dispersing cold, and unblocking the collaterals9. TCM treatments are noted for their multi-target effects, favorable side-effect profiles, and clinically significant efficacy10. Noteworthy formulations such as Buqi Tongluo Capsule (BQTL) and Fuzi Decoction (FZD) have shown clear anti-OA effects in clinical practice, while Du Huo Ji Sheng Tang (DHJST) alleviates OA symptoms by suppressing the NLRP3 inflammasome pathway, supported by centuries of empirical use. Similarly, Shenjinhuoxue Mixture (SHM) attenuates pain and cartilage degeneration through down-regulation of pro-inflammatory mediators such as IL-1β and TNF-α11,12,13. At the monomer level, compounds such as icariin (Cyanoside A, CyA) and erianin, derived from medicinal plants, have been reported to promote chondrocyte proliferation, inhibit inflammatory cytokine release, and maintain joint homeostasis14,15. Collectively, TCM offers a comprehensive therapeutic approach with anti-inflammatory, chondroprotective, and symptom-alleviating properties. However, the complexity of its mechanisms and issues related to standardization necessitate ongoing, rigorous research.
The dried ripe fruits of Fructus Xanthii (Compositae), commonly known as “Cang-Er-Zi”, have been documented to exhibit a wide range of pharmacological activities, including antimicrobial, anti-inflammatory, antioxidant, analgesic, antineoplastic, and immunomodulatory effects16. Phenolic acids isolated from Fructus Xanthii effectively reduce synovial hyperplasia in rheumatoid arthritis (RA)17. Among these, chlorogenic acid (CGA), a representative caffeoylquinic acid derivative, has been found to stimulate osteoblast proliferation and differentiation while inhibiting RANKL-mediated osteoclastogenesis, thus maintaining skeletal homeostasis18. Other phenolic acids identified within the same extract, such as neochlorogenic acid (5-CQA), cryptochlorogenic acid (CCA), and protocatechuic acid, also exhibit antimicrobial, anti-inflammatory, antitumor, and antioxidant properties19,20,21. In addition to phenolic acids, a variety of secondary metabolites present in Cang-Er-Zi contribute to these bioactivities16,20,22,23,24,25. However, the precise role and underlying mechanisms of Fructus Xanthii extract in OA remain largely unexplored.
Non-Targeted Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Metabolomics is characterized by hypothesis-free, high-throughput, and global coverage capabilities. It enables the simultaneous detection of thousands of metabolite features, providing a panoramic view of metabolic networks, and allows for the systematic discovery of novel biomarkers and aberrant metabolic pathways without prior target prespecification26,27. Combined with high-resolution mass spectrometry technology, this approach is suitable for the comprehensive analysis of various types of biological samples (e.g., serum, synovial fluid, urine, cartilage tissue, etc.) and has demonstrated significant advantages in osteoarthritis (OA) research. On the one hand, it can comprehensively screen for differential metabolites closely associated with the pathological progression of OA (such as various classes of metabolites identified in synovial fluid and synovial tissue) and map them to key pathways, including energy metabolism, cartilage repair, osteogenesis, and lipid metabolism, thereby deepening the understanding of OA pathogenesis. On the other hand, integrating multi-omics data such as transcriptomics and proteomics helps to reveal the role of metabolic reprogramming in cartilage degeneration, inflammatory responses, and joint structure damage, providing critical evidence for identifying early diagnostic biomarkers, evaluating disease progression, and developing targeted metabolic intervention strategies (e.g., regulating bile acid, tryptophan, or fatty acid metabolism), highlighting its translational potential in research on OA precision typing and personalized treatment.
Zebrafish serves as an excellent model organism due to multiple advantages: its genome is highly conserved with that of humans, sharing homology with approximately 70% of human protein-coding genes28,29. It exhibits key characteristics including rapid development, in vitro fertilization, transparent embryos enabling convenient in vivo imaging, high fecundity, and low maintenance costs30,31,32,33. In skeletal research, zebrafish allow for clear visualization of bone formation, mineralization processes, and regeneration capacity, and can be utilized to simulate pathological conditions like osteoporosis and cartilage damage. However, in the study of osteoarthritis (OA), a complex whole-joint disorder characterized by articular cartilage degeneration, synovial inflammation, and subchondral bone alterations, the application of the zebrafish model remains relatively limited.
This article presents a protocol that integrates UHPLC-HRMS/MS-based untargeted metabolomics, network pharmacology, transcriptomic mining, and in vivo experimental validation to explore the potential of Xanthium sibiricum extract as a viable plant candidate for OA intervention. The aim is not only to identify the bioactive components, potential targets, and core regulatory pathways of Xanthium sibiricum extract related to OA through multi-omics integration and computational analysis, but also to verify its chondroprotective effect on OA through in vivo models and further clarify its regulatory mechanism on chondrocyte transcriptome.
Access restricted. Please log in or start a trial to view this content.
All experiments involving clinical samples and mice were conducted in accordance with the protocol approved by the Ethics Review Committee of Shandong Provincial Medical Biotechnology Research Center. The reagents and the equipment used are listed in the Table of Materials.
1. Isolation and culture of human articular chondrocytes
Human articular cartilage specimens were obtained from patients undergoing arthroscopic surgery or total joint arthroplasty at the First Affiliated Hospital of Shandong First Medical University. Cartilage slices were transported to the laboratory on ice within 30 min of surgical excision. The tissue was washed thoroughly with ice-cold Dulbecco’s phosphate-buffered saline (DPBS; 3–5 washes), then minced finely into approximately 1 mm3 fragments using sterile surgical scissors. Sequential enzymatic digestion was performed, beginning with pre-digestion using 0.25% trypsin-EDTA for 30 min at 37 °C. The digestion process was monitored until the cartilage fragments became thinned, reduced in size, and translucent, after which the cartilage fragments were collected by centrifugation (200 × g, 5 min) at room temperature. This was followed by overnight digestion (8 h, 37 °C) with 0.2% type II collagenase under continuous gentle agitation. The digestion process was monitored until all macroscopically visible cartilage fragments were completely dissolved. The released cells were collected by centrifugation (200 × g, 5 min) at room temperature, resuspended in complete DMEM supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin, and seeded into 75 cm2 culture flasks. Cells were maintained at 37 °C in a humidified atmosphere containing 5% CO2. Adherent chondrocytes were detached using 0.25% trypsin-EDTA, and the cells were subcultured at a 1:3 ratio when the adherent cells reached 80% confluence of the culture flask surface.
2. Preparation of Fructus Xanthii extract
Dried ripe fruits of Xanthium strumarium L. (Fructus Xanthii) were collected from naturally occurring populations in North China and authenticated by a senior pharmacognosist. The specimen was deposited in the herbarium of Shandong First Medical University. 20 g of finely powdered Fructus Xanthii were placed into an extraction thimble, and exhaustive Soxhlet extraction was performed using 95% ethanol (approximately 250 mL) until seven to eight siphon cycles were completed. The ethanolic extract was filtered, and the filtrate was concentrated to dryness under reduced pressure at 45 °C using a rotary evaporator. The resulting residue was resuspended in 60 mL of double-distilled water and partitioned successively with 60 mL of ethyl acetate in a separatory funnel. The mixture was shaken vigorously and allowed to undergo phase separation at 4 °C for 24 h. The aqueous layer was then collected, lyophilized, and stored at −80 °C until further use.
3. Standardized workflow for non-targeted LC-MS/MS metabolomics
4. Network pharmacology analysis
5. Determination of Maximum Tolerated Concentration (MTC) in zebrafish
Transgenic zebrafish larvae (Tg col2a1a:EGFP) at 2 days post-fertilization (2 dpf) were randomly distributed into 6-well plates at a density of 30 larvae per well. Each well was supplemented with 3 mL of exposure medium containing serially diluted Fructus Xanthii extract. Moribund or deceased larvae were removed daily. The larvae were continuously exposed at 28 °C for 72 h, after which the maximum tolerated concentration (MTC) was determined as the highest concentration at which larval mortality did not exceed 10%.
6. Establishment of the zebrafish bone-injury model
Tg col2a1a:EGFP zebrafish larvae at 2 days post-fertilization (2 dpf) were assigned to four groups: control, model, chondroitin sulfate (CS) positive control, and Fructus Xanthii extract treatment. All groups except the control group were exposed to Staphylococcus aureus (OD600 = 0.8, 1 × 108 CFU/mL) for 24 h to induce bone injury. Successful model establishment was confirmed by verifying a reduction of at least 50% in cartilage-specific green fluorescence intensity in the craniofacial region relative to the control group under an epifluorescence microscope.
7. Quantitative assessment of cartilage-specific fluorescence in zebrafish larvae
The larvae were exposed continuously to graded concentrations of Fructus Xanthii extract or 1,000 µg/mL sodium chondroitin sulfate A (positive control) at 28 °C for 72 h. Subsequently, 10 larvae were randomly selected from each 6-well replicate (n = 30 per group). The selected larvae were anesthetized using 0.016% tricaine and positioned laterally on 1% low-melting agarose pads. Fluorescence images were acquired at 2× magnification (excitation 488 nm, emission 525/50 nm) using a stereomicroscope equipped with a fluorescence camera. Cartilage-specific EGFP intensity in the craniofacial region, including the ceratohyal and Meckel’s cartilage, was quantified using image analysis software. Background correction was performed on the integrated density values, and the corrected values were normalized to the control group for statistical analysis of chondroprotective efficacy.
8. Induction of OA in C57BL/6J mice
Male C57BL/6J mice (6–8 weeks old, 20–22 g) were housed under specific pathogen-free (SPF) conditions at 22 °C ± 2 °C with a 12 h light/dark cycle. The mice were allowed to acclimatize for one week and were then randomly assigned into three groups (n = 8 per group) using a random number table: (1) sham-operated control, (2) ACLT-induced OA (ACLT), and (3) ACLT plus Fructus Xanthii extract intervention (ACLT + Fructus Xanthii extract). All surgical procedures were performed under sterile conditions in accordance with a previously validated protocol.
The mice were anesthetized with intraperitoneal sodium pentobarbital (50 mg/kg) (following institutionally approved protocols), and a medial parapatellar incision was made to expose the right knee joint capsule. The anterior cruciate ligament was transected under an operating microscope to induce joint instability, after which the joint capsule and skin were closed in layers using 6-0 absorbable sutures. Sham-operated mice underwent identical arthrotomy procedures without ligament transection. Joint stability was evaluated, and successful model establishment was confirmed by performing the drawer test or by assessing the degree of joint injury in histological sections from the model group mice.
Postoperative analgesia with buprenorphine (0.1 mg/kg, subcutaneous injection) was administered for three consecutive days. The treatment agents were administered once daily by gavage. The ACLT + Fructus Xanthii extract group received 100 µL of 1,000 µg/mL Fructus Xanthii extract diluted in normal saline, whereas the other two groups received 100 µL of normal saline as the vehicle control. At 8 weeks post-surgery, the mice were euthanized by CO2 asphyxiation followed by cervical dislocation, and the knee joints were harvested for histological analyses.
9. Histopathological staining
10. RNA-sequencing (RNA-seq)
Primary human articular chondrocytes (passages 2–3) were seeded into 6-well plates at a density of 5 × 105 cells per well. The cells were serum-starved for 24 h and then allocated into two groups (n = 3 per group): (1) Control group: cells were treated with vehicle only (0.1% DMSO); (2) Fructus Xanthii extract group: cells were treated with 1,000 µg/mL Fructus Xanthii extract dissolved in DMSO.
The cells were treated for 24 h, after which total RNA was extracted using TRIzol Reagent according to the manufacturer’s protocol. RNA integrity (RIN ≥7.0) and concentration were assessed using an RNA analyzer. Strand-specific cDNA libraries were prepared using an RNA sequencing library preparation kit and sequenced on a high-throughput next-generation sequencing (NGS) platform in paired-end 150 bp (PE150) mode. Quality control of the raw FASTQ files was performed using FastQC, followed by adapter and quality trimming using Trimmomatic prior to downstream analysis.
11. RNA-seq data processing
Differentially expressed genes downregulated by Fructus Xanthii extract (vs. control group; p < 0.05 and logFC < −0.5) were extracted from the RNA-seq dataset and intersected with the top 10 hub targets. The resulting core targets associated with Fructus Xanthii extract and osteoarthritis were visualized using the ggvenn package.
12. ELISA
Primary human articular chondrocytes at passages 2–3 were seeded in 6-well plates at a density of 5 × 105 cells per well. Cells were incubated in serum-free medium for 24 h to induce quiescence. The cells were subsequently divided into the following three groups (n = 3 per group):
(1) Blank control: cells were treated with vehicle (0.1% DMSO) only; (2) Positive control: cellular inflammation was induced with IL-1β, followed by treatment with vehicle (0.1% DMSO); (3) Fructus Xanthii extract group: cellular inflammation was induced with IL-1β, followed by treatment with 1000 µg/mL Fructus Xanthii extract dissolved in 0.1% DMSO. Cell culture supernatants were collected after 24 h of incubation and stored at −80 °C until use. Levels of MMP1 and PGR in the culture supernatants were determined using commercially available enzyme-linked immunosorbent assay (ELISA) kits specific for human MMP1 and PGR, respectively. The assays were performed according to the manufacturers’ instructions.
13. Statistical analysis
All statistical analyses were performed using statistical analysis and graphing software, and data were presented as mean ± standard deviation (SD). Data normality was assessed using the Shapiro–Wilk test, and homoscedasticity was evaluated using the Levene test. Inter-group comparisons were performed using one-way or two-way analysis of variance (ANOVA), followed by Tukey’s or Šidák post-hoc tests, as appropriate. Pairwise comparisons were conducted using a two-tailed Student’s t-test. Non-parametric data were analyzed using the Mann–Whitney U test. A two-sided P-value < 0.05 was considered statistically significant.
Access restricted. Please log in or start a trial to view this content.
Quality assessment and metabolic landscape of non-targeted LC-MS/MS data
QC samples demonstrated excellent reproducibility, as indicated by highly overlapping TIC chromatograms in both positive and negative ion modes, with retention time drift remaining below 0.05 min across the entire analytical batch. Raw data underwent XCMS-based preprocessing, which included peak detection, integration, and retention-time alignment. Putative metabolites were annotated by matching accurate ...
Access restricted. Please log in or start a trial to view this content.
OA is a prevalent degenerative joint disorder and a leading cause of disability worldwide36. Its pathogenesis is complex and multifactorial, involving biochemical, cellular, and molecular changes across joint tissues. Once considered a simple "wear-and-tear" phenomenon of articular cartilage, OA is now widely recognized as a chronic, whole-joint disease characterized by cartilage degradation, synovial inflammation, osteophyte formation, and subchondral bone remodelling37<...
Access restricted. Please log in or start a trial to view this content.
The authors declare no known competing financial interests or personal relationships that could have influenced the work reported in this paper.
This research was financially supported by the Shandong Province Nature Fund Surface Project Grant (No. ZR2024MH088), the Shandong Province Traditional Chinese Medicine Technology Project (No. 2020M070), and Cultivation Fund of The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital (Grant No. QYPY2022NSFC0601)”.
Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| 4% PFA | Biosharp, China | BL539A | pH 7.4, sterile |
| C57BL/6 Mice | Vital River Laboratory Animal Technology Co.,Ltd, China | N/A | Male, 8-10 weeks old, 20-25g |
| Chondroitin sulfate | MCE, America | HY-B2162 | Purity ≥98% |
| ClusterProfiler (R Package) | Bioconductor | Free access | Integrated in R v4.2.2 |
| Collagenase, Type II, powder | Gibco, America | 17101015 | ≥125 U/mg |
| Cytoscape | Cytoscape Consortium | Free access (https://cytoscape.org/) | v3.9.1 (with CytoHubba) |
| Cytoscape | Cytoscape Consortium | Free access | Version 3.9.1 |
| DESeq2 (R Package) | Bioconductor | Free access | Integrated in R v4.2.2 |
| DMEM, high glucose | Gibco, America | 11965092 | Sterile medium |
| Ethanol | Sinopharm Chemical Reagent Co.,Ltd, China | 10009218 | Analytical grade, 95% |
| Ethyl acetate | Sinopharm Chemical Reagent Co.,Ltd, China | 10009418 | Analytical grade |
| Fetal bovine serum (FBS) | Cellmax, China | SA102.02 | Heat-inactivated |
| Fluorescence Microscope | Nikon, Japan | Eclipse Ti2-U | Equipped with GFP filter (488nm excitation) & digital camera |
| GEO Database | NCBI | https://www.ncbi.nlm.nih.gov/geo/geo2r | GEO2R analysis tool |
| GraphPad Prism | GraphPad Software, LLC, America | Commercial | Version 9.5.1 |
| Hematoxylin-Eosin(HE) Stain Kit | Solarbio, China | G1120 | Ready-to-use kit |
| HERB Database | Chinese Academy of Sciences | http://herb.ac.cn/ | V2.0 |
| Human MMP-1 ELISA Kit | Yamei Biotechnology, China | HJ088 | For human, 96-well plate |
| Human Progesterone Receptor (PR) ELISA Kit | Shanghai Enzyme-Linked Biotechnology Co., Ltd., China | ml05997 | For human, 96-well plate |
| ImageJ | National Institutes of Health (NIH) | Free access | Version 1.53t |
| Light Microscope | Olympus, Japan | BX53 | 10×/20× objectives & digital camera |
| Lyophilizer | Christ, Germany | Alpha 1-4 LDplus | Freeze-drying system |
| Modified Saffron-O And Fast Green Stain Kit | Solarbio, China | G1371 | For bone/cartilage staining |
| Neutral Balsam | Solarbio, China | G8590 | Mounting medium |
| Penicillin-Streptomycin | Gibco, America | 15070063 | 100×, sterile |
| Phosphate-buffered saline (PBS) | Sparkjade, China | CR0013-500ML | pH 7.2-7.4, sterile |
| R software | R Foundation for Statistical Computing | Free access (https://www.r-project.org/) | v4.4.1 (with ggvenn) |
| Serum-free Cell Freezing Medium | Biosharp, China | BL203B | Sterile |
| Staphylococcus aureus | American Type Culture Collection (ATCC) | ATCC 25923 | Standard strain |
| STRING Database | STRING Consortium | https://string-db.org/ | Protein interaction analysis |
| TCMID Database | Shaanxi Qinling Qiyao Collaborative Innovation Center | https://www.tcmsp-e.com/tcmspsearch.php | V3.0 |
| Tg(col2a1a:EGFP) Zebrafish | Zebrafish International Resource Center (ZIRC) | N/A | Larvae (2 dpf), AB strain |
| TRIzol Reagent | Thermo Fisher, America | 15596018CN | For total RNA extraction |
| Trypsin-EDTA (0.25%), phenol red | Gibco, America | 25200056 | Sterile solution |
| Ultra-high Performance Liquid Chromatography (UHPLC) | Thermo Fisher, America | Q Exactive Focus | Coupled with HRMS/MS |
| XCMS-online | Scripps Research Institute | Free access | Web-based platform |
Request permission to reuse the text or figures of this JoVE article
Request Permission